Generally, DNMT inhibitors function by inhibiting DNA methylation in order to decrease the level of promoter hypermethylation and enable abnormally silenced tumour suppressor genes such as P15 or CDKN2B, P16 or CDKN2A, MLH1, and RB to re‐express.136. This evidence concerns the gene CDKN2B and neoplasm.